SEC Form EFFECT filed by Cardio Diagnostics Holdings Inc.
UNITED STATES | |
SECURITIES AND EXCHANGE COMMISSION | |
Washington, D.C. 20549 | |
Notice of Effectiveness | |
Effectiveness Date: | February 14, 2025 5:00 P.M. |
Form: | S-3 | ||||||
|
UNITED STATES | |
SECURITIES AND EXCHANGE COMMISSION | |
Washington, D.C. 20549 | |
Notice of Effectiveness | |
Effectiveness Date: | February 14, 2025 5:00 P.M. |
Form: | S-3 | ||||||
|
Save time and jump to the most important pieces.
Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), an AI-driven precision cardiovascular medicine company, today announced the appointment of Dr. Vimal Ramjee, MD FACC CCMS, as a Strategic Advisor. Dr. Ramjee is a cardiologist and a health innovation leader, serving as the National Co-Chair of Cardiology and Innovation at CommonSpirit Health Enterprise and is also a member of the American Heart Association Board of Directors. The appointment of Dr. Ramjee as a Strategic Advisor to Cardio Diagnostics is a significant development to the Company's continued growth and market expansion. He brings a wealth of experience and proven track record in clinical practice, innovation and research, makin
Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), an AI-driven precision cardiovascular medicine company, today announced the appointment of Paul Burton, J.D., MBA to its Board of Directors as an Independent Director. Mr. Burton will Chair the Nominating and Corporate Governance Committee and will also serve as a member of the Audit Committee. Mr. Burton is the Managing Partner at 2Flo Ventures, an early-stage healthcare investor and startup studio focused on accelerating health equity. He is also the CEO of Akan Biosciences, a clinical-stage biotech company, and runs an advisory firm working closely with healthcare growth companies. Mr. Burton brings over 20 years of experience in medical
SC 13G/A - Cardio Diagnostics Holdings, Inc. (0001870144) (Subject)
4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)
4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)
4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)
8-K - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)
10-Q - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)
8-K - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)
Cardio Diagnostics Holdings Inc. (NASDAQ:CDIO), an artificial intelligence-powered precision cardiovascular medicine company, today announced that the Japan Patent Office has issued a patent for another set of biomarkers in the company's intellectual property portfolio. The patent, titled "Compositions and Methods for Detecting Predisposition to Cardiovascular Disease," (Japanese Patent No. 7672192) is exclusively licensed to Cardio Diagnostics from the University of Iowa Research Foundation (UIRF) and names Cardio Diagnostics' founders Meesha Dogan, Ph.D., Chief Executive Officer, and Robert Philibert, MD, Ph.D., Chief Medical Officer, as inventors. The Japanese patent further strengthen
Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) ("Cardio Diagnostics" or the "Company"), a pioneer in AI-powered precision cardiovascular medicine, today announced that on May 28, 2025, it received a notification letter (the "Notification Letter") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it had regained compliance with the minimum bid price requirement set forth in the Nasdaq Listing Rule 5550(a)(2) ("Minimum Bid Requirement") for continued listing on The Nasdaq Capital Market. This was disclosed in the Company's Current Report on Form 8-K filed on May 28, 2025. The Nasdaq staff made this determination of compliance af
Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), a pioneer in AI-powered precision cardiovascular medicine, today announced the continued expansion of its reach with a new cohort of healthcare practices across the United States now offering its innovative clinical blood tests, Epi+Gen CHD™ and PrecisionCHD™. This group of adopters spans a wide range of care models - from concierge and direct primary care to functional and integrative medicine, demonstrating the growing appetite for proactive, personalized cardiovascular care. These latest adopters are primarily independent practices deeply committed to modernizing the patient experience and championing heart disease prevention and early d
4/A - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)
4/A - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)
4/A - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)